人物经历

工作经历

曾任广东省肺癌研究所副所长，肺五科主任。

现任广东省人民医院广东省肺癌研究所所长、惠福分院副院长1。

学术兼职

CSCO理事，青委副主委，肺癌专业组长，国家自然科学基金评委，中华医学会肿瘤分会早筛早诊副组长，国际肺癌联盟IASLC官方杂志(J Thorac Oncol，IF 10.4)JTO associate editor。

学术成果

主要方向以肺癌外科为主单病种多学科综合治疗，包括IIIA期N2肺癌、肺部孤立结节/肺腺癌/GGO分类诊断和处理、多原发肺结节，胸腔镜微创肺癌根治术、肺癌病理分类、人工智能影像-液体活检肺癌早筛分诊系统等；主持四项国家自然科学基金（靶向耐药分子T790M分子演化-2010；肺腺癌分子演化-2013；高级别神经内分泌肿瘤DLL3分子异质性-2016）；肺癌影像组学-2018；研究结果发表在lancet oncol（IF 34），JCO（IF 24）, CCR, Cancer，Oncologist，J Thorac Oncol，Lung Cancer，JHO，Eur J Cardiothorac Surg，Ann Surg Oncol，BMC Cancer，Clin Lung Cancer，Cancer Lett，JTD等杂志。

参与《中国临床肿瘤学会原发性肺癌诊疗指南》制定，共同主编《细支气管肺泡癌》《肺腺癌病理新分类和临床实践》，参编高级卫生专业技术资格考试指导用书《临床肿瘤学高级教程》，研究生卫生部规划教材《胸心外科学》肺腺癌新分类和肺癌个体化外科章节，执行主编《中国临床肿瘤学年度研究进展 2015-2018》。

荣誉记录

2015年，代表肺研所团队参加中日韩肺癌个体化诊疗大赛中国区冠军和总决赛冠军。

2016年，获中国医师协会胸外科医师菁英手术技艺大赛中国第一名（腔镜肺切除组）。

2016年，获AME国际单孔胸腔镜肺叶切除比赛亚军。

2025年4月28日，中共中央、国务院授予钟文昭全国先进工作者荣誉称号1。

发表论文

1. Zhong W-Z, Wang Q, Mao W-M, Xu S-T, Wu L, Shen Y, Liu Y-Y, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li X-F, Li J, Huang C, Liu Z-D, Xu S, Chen K-N, Xu S-D, Liu L-X, Yu P, Wang B-H, Ma H-T, Yan H-H, Yang X-N, Zhou Q, Wu Y-L, Wu Y-L, Wang Q, Mao W-M, Wu L, Shen Y, Liu Y-Y, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li X-F, Li J, Huang C, Liu Z-D, Xu S, Chen K-N, Xu S-D, Liu L-X, Yu P, Wang B-H, Ma H-T, Wang S-Y, Hu J, Liu W, Li W, Shi J-H. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. The Lancet Oncology 2018;19: 139-148.

2. Zhong WZ, Liu SY, Wu YL. Numbers or Stations: From Systematic Sampling to Individualized Lymph Node Dissection in Non-Small-Cell Lung Cancer. J Clin Oncol 2017;35: 1143-1145.3. Zhong W, Yang X, Yan H, Zhang X, Su J, Chen Z, Liao R, Nie Q, Dong S, Zhou Q, Yang J, Tu H, Wu YL. Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. J Hematol Oncol 2015;8: 54.4. Gou LY, Niu FY, Wu YL, Zhong WZ(Corresponding authors). Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population. Cancer 2015;121 Suppl 17: 3069-3079.5. Zhong WZ, Su J, Xu FP, Zhai HR, Zhang XC, Yang XN, Chen ZY, Chen ZH, Li W, Dong S, Zhou Q, Yang JJ, Liu YH, Wu YL. Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers. Lung Cancer 2015;90: 205-211.6. Guan JL, Zhong WZ(co-first author), An SJ, Yang JJ, Su J, Chen ZH, Yan HH, Chen ZY, Huang ZM, Zhang XC, Nie Q, Wu YL. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Ann Surg Oncol 2013;20: 1381-1388.7. Zhai HR, Yang XN, Nie Q, Liao RQ, Dong S, Li W, Jiang BY, Yang JJ, Zhou Q, Tu HY, Zhang XC, Wu YL, Zhong WZ(Corresponding authors). Different dissecting orders of the pulmonary bronchus and vessels during right upper lobectomy are associated with surgical feasibility and postoperative recovery for lung cancer patients. Chin J Cancer 2017;36: 53.8. Chen ZY, Zhong WZ(co-first author), Zhang XC, Su J, Yang XN, Chen ZH, Yang JJ, Zhou Q, Yan HH, An SJ, Chen HJ, Jiang BY, Mok TS, Wu YL. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 2012;17: 978-985.9. Dong ZY, Zhang JT, Liu SY, Su J, Zhang C, Xie Z, Zhou Q, Tu HY, Xu CR, Yan LX, Li YF, Zhong WZ(co-Corresponding authors), Wu YL. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology 2017;6: e1356145.10. Dong ZY, Zhai HR, Hou QY, Su J, Liu SY, Yan HH, Li YS, Chen ZY, Zhong WZ(co-Corresponding authors), Wu YL. Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer. Oncologist 2017;22: 61-69.11. Lin H, Zhong WZ(co-first author), Yang XN, Zhang XC, Yang JJ, Zhou Q, Yan HH, Liao RQ, Nie Q, Dong S, Wu YL. A clinical model to estimate the pretest probability of lung cancer, based on 1198 pedigrees in China. J Thorac Oncol 2012;7: 1534-1540.12. Zhong WZ, Li W, Yang XN, Liao RQ, Nie Q, Dong S, Yan HH, Zhang XC, Tu HY, Wang BC, Su J, Yang JJ, Zhou Q, Wu YL. Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis. J Thorac Dis 2015;7: 1205-1212.13. Li W, Yang XN, Liao RQ, Nie Q, Dong S, Zhai HR, Wu YL, Zhong WZ(Corresponding authors). Intraoperative frozen sections of the regional lymph nodes contribute to surgical decision-making in non-small cell lung cancer patients. J Thorac Dis 2016;8: 1974-1980.14. Zhai HR, Nie Q, Dong S, Yang XN, Wu YL, Zhong WZ(Corresponding authors). Right upper lobectomy performed as dividing posterior ascending artery-bronchus-pulmonary vessels is alternative to primary indolent scar carcinomas. J Thorac Dis 2016;8: 1340-1344.15. Li W, Yang XN, Liao RQ, Nie Q, Dong S, Zhai HR, Wu YL, Zhong WZ(Corresponding authors). Intraoperative frozen sections of the regional lymph nodes contribute to surgical decision-making in non-small cell lung cancer patients. J Thorac Dis 2016;8: 1974-1980.16. Li F, Zhong WZ(co-first author), Niu FY, Zhao N, Yang JJ, Yan HH, Wu YL. Multiple primary malignancies involving lung cancer. BMC Cancer 2015;15: 696.17. Zhong WZ, Wu YL, Yang XN, Guo AL, Su J, Zhang XC, Luo DL, Wang Z, Chen HJ, Zhou Q, Xu CR, Qiao GB, Liao RQ, Yang JJ, Mok TS. Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component. Clin Lung Cancer 2010;11: 160-168.18. Zhong W, Yang X, Bai J, Yang J, Manegold C, Wu Y. Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer. Eur J Cardiothorac Surg 2008;34: 187-195.19. Jinji Yang, Xu-Chao Zhang, Jian Su, Chongrui Xu, Qing Zhou, Hong-Xia Tian, Zhi Xie, Hua-Jun Chen, Yi-Sheng Huang, Ben-Yuan Jiang, Zhen Wang, Bin-Chao Wang, Xuening Yang, Wenzhao Zhong, Qiang Nie, Ri-Qiang Liao, Tony S.K. Mok, and Yi-Long Wu. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res. Published Online First January 17, 2014; doi:10.1158/ 1078-0432. CCR-13-069920. Xu-chao Zhang, Jingchuan Zhang, Ming Li, Xiao-sui Huang, Xue-ning Yang, Wen-zhao Zhong, Liang Xie, Lin Zhang, Minhua Zhou, Paul Gavine, Xinying Su, Li Zheng, Guanshan Zhu, Ping Zhan, Qunsheng Ji, Yi-long Wu. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. Journal of Translational Medicine. 2013;11: 168.21. Yang JJ, Chen HJ, Yan HH, Zhang XC, Zhou Q, Su J, Wang Z, Xu CR, Huang YS,Wang BC, Yang XN, Zhong WZ, Nie Q, Liao RQ, Jiang BY, Dong S, Wu YL. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management inadvanced non-small cell lung cancer. Lung Cancer. Lung Cancer. 2013 Jan;79(1):33-9.22. She-Juan An, Zhi-Hong Chen, Jian Su, Xu-Chao Zhang, Wen-Zhao Zhong, Jin-Ji Yang, Qing Zhou, Xue-Ning Yang, Ling Huang, Ji-Lin Guan, Qiang Nie, Hong-Hong Yan, Tony S. Mok, Yi-Long Wu. Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status. PLoS ONE, 2012; 7(6): e40109. doi:10.1371/ journal.pone. 004010

23. Wu Y-L, Zhong W-Z, Li L-Y, Zhang X-T, Zhang L, Zhou C-C, Liu W, Jiang B, Mu X-L, Lin J-Y et al: Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small-cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in Chinese mainland. J Thorac Oncol 2007, 2(5):430-439.24. Zhu JQ, Zhong WZ, Zhang GC, Li R, Zhang XC, Guo AL, Zhang YF, An SJ, Mok TS, Wu YL: Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Lett 2008, 265(2):307-317.25. Pan XH, Zhong WZ, Xiang MX, Xu G, Shan J, Wang JA: Clinical outcomes of serolimus-eluting stents versus bare metal stents in ST-segment elevation myocardial infarction patients: a meta-analysis. Chinese medical journal 2009, 122(1):88-92.26. Qiao GB, Wu YL, Yang XN, Zhong WZ, Xie D, Guan XY, Fischer D, Kolberg HC, Kruger S, Stuerzbecher HW: High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 2005, 93(1):137-143.27. Qiu LX, Li RT, Zhang JB, Zhong WZ, Bai JL, Liu BR, Zheng MH, Qian XP: The E-cadherin (CDH1)--160 C/A polymorphism and prostate cancer risk: a meta-analysis. Eur J Hum Genet 2009, 17(2):244-249.28. Qiao GB, Zeng WS, Peng LJ, Zhong WZ, Fang Y, Huang WJ, Wu YL: Multiple pulmonary chondromas in a young female patient: a component of Carney triad. J Thorac Oncol 2009, 4(6):751-752.29. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, Wang BC, Huang YS, Wang Z, Wu YL: Relative Abundance of EGFR Mutations Predicts BenefitFrom Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer. J Clin Oncol 2011, August 1, 29 (22).30. Nie Q , Yang XN , An SJ , Zhang XC , Yang JJ , Zhong WZ , Liao RQ , Chen ZH , Su J , Xie Z , Wu YL: CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. Eur J Cancer 2011 May 25.

擅长领域